• Dyne Therapeutics amended its senior secured term loan facility with Hercules Capital, expanding total capacity to up to $400 million.
• The amendment funded $50 million at closing, lifting total borrowings under the facility to $200 million across three tranches.
• Added a $50 million tranche available at Dyne’s option, subject to milestone achievements.
• Increased the final tranche by $25 million to up to $75 million, subject to Hercules’ discretion.
• Dyne retains access to up to $200 million of potential future funding under the facility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief on June 17, 2026, and is solely responsible for the information contained therein.